Research Analysts’ Recent Ratings Changes for Regeneron Pharmaceuticals (REGN)

A number of firms have modified their ratings and price targets on shares of Regeneron Pharmaceuticals (NASDAQ: REGN) recently: 11/6/2024 – Regeneron Pharmaceuticals had its price target lowered by analysts at Oppenheimer Holdings Inc. from $1,150.00 to $1,000.00. They now have an “outperform” rating on the stock. 11/4/2024 – Regeneron Pharmaceuticals was downgraded by analysts […]

Leave a Reply

Your email address will not be published.

Previous post Focus Impact Acquisition Corp. Completes Merger with DevvStream Holdings Inc. and Rebrands as DevvStream Corp.
Next post Heritage Financial (NASDAQ:HFWA) Hits New 52-Week High – What’s Next?